JP2017537888A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537888A5
JP2017537888A5 JP2017522654A JP2017522654A JP2017537888A5 JP 2017537888 A5 JP2017537888 A5 JP 2017537888A5 JP 2017522654 A JP2017522654 A JP 2017522654A JP 2017522654 A JP2017522654 A JP 2017522654A JP 2017537888 A5 JP2017537888 A5 JP 2017537888A5
Authority
JP
Japan
Prior art keywords
polypeptide
fusion protein
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522654A
Other languages
English (en)
Japanese (ja)
Other versions
JP6737781B2 (ja
JP2017537888A (ja
Filing date
Publication date
Priority claimed from US14/524,832 external-priority patent/US10400029B2/en
Application filed filed Critical
Priority claimed from PCT/US2015/057533 external-priority patent/WO2016069574A1/en
Publication of JP2017537888A publication Critical patent/JP2017537888A/ja
Publication of JP2017537888A5 publication Critical patent/JP2017537888A5/ja
Application granted granted Critical
Publication of JP6737781B2 publication Critical patent/JP6737781B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522654A 2014-10-27 2015-10-27 セルピン融合ポリペプチド及びその使用方法 Active JP6737781B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/524,832 2014-10-27
US14/524,832 US10400029B2 (en) 2011-06-28 2014-10-27 Serpin fusion polypeptides and methods of use thereof
PCT/US2015/057533 WO2016069574A1 (en) 2014-10-27 2015-10-27 Serpin fusion polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020121953A Division JP2020180157A (ja) 2014-10-27 2020-07-16 セルピン融合ポリペプチド及びその使用方法

Publications (3)

Publication Number Publication Date
JP2017537888A JP2017537888A (ja) 2017-12-21
JP2017537888A5 true JP2017537888A5 (https=) 2018-10-25
JP6737781B2 JP6737781B2 (ja) 2020-08-12

Family

ID=55858243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017522654A Active JP6737781B2 (ja) 2014-10-27 2015-10-27 セルピン融合ポリペプチド及びその使用方法
JP2020121953A Pending JP2020180157A (ja) 2014-10-27 2020-07-16 セルピン融合ポリペプチド及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020121953A Pending JP2020180157A (ja) 2014-10-27 2020-07-16 セルピン融合ポリペプチド及びその使用方法

Country Status (15)

Country Link
EP (1) EP3212290A4 (https=)
JP (2) JP6737781B2 (https=)
KR (2) KR20170091096A (https=)
CN (2) CN114316068A (https=)
AU (3) AU2015339507B2 (https=)
BR (1) BR112017008525A2 (https=)
CA (1) CA2965151A1 (https=)
HK (1) HK1244460A1 (https=)
IL (2) IL251799B2 (https=)
MX (2) MX2017005467A (https=)
NZ (1) NZ769391A (https=)
RU (1) RU2746550C2 (https=)
SG (2) SG11201703390SA (https=)
UA (1) UA127305C2 (https=)
WO (1) WO2016069574A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
WO2020097946A1 (zh) * 2018-11-18 2020-05-22 杭州博虎生物科技有限公司 一种重组人白细胞介素10融合蛋白及其应用
CN112315897A (zh) * 2020-11-04 2021-02-05 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法
WO2022133521A1 (en) * 2020-12-21 2022-06-30 Macquarie University Treatment of glaucoma
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
EP4301333A2 (en) * 2021-03-03 2024-01-10 Formycon AG Formulations of ace2 fc fusion proteins
CN113325181A (zh) * 2021-04-25 2021-08-31 苏州市立医院(北区) 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
US20230364208A1 (en) 2022-05-16 2023-11-16 Inhibrx, Inc. Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject
EP4705336A1 (en) * 2023-05-05 2026-03-11 Paul Thomas King Novel therapeutic polypeptide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3609300A (en) * 1999-03-01 2000-09-21 Human Genome Sciences, Inc. Human serpin proteins
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1646642A2 (en) * 2003-07-18 2006-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
DK1817340T3 (da) * 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1910542B1 (en) * 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
MX2008002101A (es) * 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
EP2307456B1 (en) * 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2376109B1 (en) * 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
CA2822366A1 (en) * 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
SG10201602394QA (en) * 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
CN110551223A (zh) * 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
AU2013202648B2 (en) * 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
TW201402611A (zh) * 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
WO2014001325A1 (en) * 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CN104508132B (zh) * 2012-08-02 2017-09-15 弗·哈夫曼-拉罗切有限公司 用于产生作为与惰性免疫球蛋白Fc区Fc融合的可溶FcR的方法及其用途
JP6345688B2 (ja) * 2012-12-05 2018-06-20 ソラ・バイオサイエンシズ・エルエルシー タンパク質発現増強ポリペプチド

Similar Documents

Publication Publication Date Title
JP2017537888A5 (https=)
JP2024138397A5 (https=)
RU2017118325A (ru) Слитые серпиновые полипептиды и способы их применения
NZ744257A (en) Serpin fusion polypeptides and methods of use thereof
JP6920230B2 (ja) アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物
JP2022043042A5 (https=)
JP2020171316A (ja) アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2010524971A5 (https=)
JP2018070625A5 (https=)
CN113173995B (zh) 一种结合冠状病毒的双特异性抗体
JP2015504675A5 (https=)
JP2018537087A5 (https=)
JP2014530611A5 (https=)
CN103396479A (zh) α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法
JP6938565B2 (ja) Ｕｔｉ融合タンパク質
JP2008507298A5 (https=)
JP2007509984A5 (https=)
JP2020019813A5 (https=)
CN107226842B (zh) 靶向pd-1的多肽及其应用
CN101225110A (zh) 人白细胞介素-22突变体及其构建方法和应用
JP2009507503A5 (https=)
CN102690354A (zh) 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达系统
WO2012048653A1 (zh) 干扰素-白蛋白结合肽的融合蛋白及其用途
CN103333255A (zh) 一种长效hiv‐1膜融合抑制剂
JP2009536821A5 (https=)